Skip to main content

OrbiMed — Portfolio, Page 9

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

289
Companies
$23.6B
Total invested
$104.0M
Avg. check
14
Industries
Biotechnology 20Health Care 13Therapeutics 10Medical 8Pharmaceutical 5Biopharma 5+8 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 193216 of 289
MBX Biosciences
August 2024

MBX Biosciences is a preclinical-stage biotech company that creates therapies to treat rare endocrine diseases.

Biotechnology · Carmel$63.5M Series C
Chemomab
July 2024

Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics.

Biotechnology · Tel Aviv$10.0M Post Ipo Equity
Brenig Therapeutics
July 2024

Brenig Therapeutics develops therapies for neurodegenerative disorders.

Health Care · Dover$65.0M Series A
Magenta Medical
July 2024

Magenta Medical is engaged in the development of novel device solutions for the treatment of acute and chronic heart failure.

Health Care · Kadima$105.0M Series Unknown
Belenos Biosciences
July 2024

Belenos Biosciences is a company.

New York$48.0M Seed
Vanqua Bio
July 2024

Vanqua Bio is a biotechnology company that discovers and develops next-generation medicines for patients with neurodegenerative diseases.

Biotechnology · Chicago$45.0M Series Unknown
Vigil Neuroscience
June 2024

Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.

Biotechnology · Cambridge$40.0M Post Ipo Equity
Exsilio Therapeutics
June 2024

Exsilio develops genomic therapeutics that introduce therapeutic genes into safe shelters within the DNA.

Biotechnology · Boston$82.0M Series A
Cullinan Therapeutics
April 2024

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics used to end a drug program quickly.

Biopharma · Cambridge$280.0M Post Ipo Equity
Alterome Therapeutics
April 2024

Alterome Therapeutics is a biopharmaceutical company developing alteration-specific targeted therapies.

Biopharma · San Diego$132.0M Series B
Capstan Therapeutics
March 2024

Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases.

Biotechnology · San Diego$175.0M Series B
ImmPACT Bio
February 2024

ImmPACT Bio USA is developing novel cell therapies for treating cancer.

Biotechnology · Camarillo$8.0M Grant
Pinnacle Medicines
February 2024

Pinnacle Medicines is a peptide drug discovery company that provides peptide modality for medical needs.

Biopharma · Doylestown$600K Series A
Tyra Biosciences
February 2024

Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.

Biotechnology · Carlsbad$200.0M Post Ipo Equity
Keros Therapeutics
January 2024

Keros is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of novel treatments.

Biotechnology · Lexington$140.0M Post Ipo Equity
SpringWorks Therapeutics
December 2023

SpringWorks Therapeutics is a biopharmaceutical company that develops medicines for patients with severe rare diseases and cancer.

Biopharma · Stamford$275.0M Post Ipo Equity
Koya Medical
November 2023

Koya Medical is a transformative healthcare company developing breakthrough treatments for lymphedema and venous diseases.

Biotechnology · Oakland$30.0M Series C
Alpine Immune Sciences
November 2023

Alpine Immune Sciences is an immunotherapy company focused on developing treatments for autoimmune and inflammatory diseases.

Biotechnology · Seattle$150.0M Post Ipo Equity
Terremoto Biosciences
November 2023

Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines.

Biotechnology · San Francisco$175.0M Series B
Forward Therapeutics
October 2023

Forward Therapeutics is a biopharma comapny targeting treatment of chronic inflammatory disorders.

Health Care · Palm Beach Gardens$50.0M Series A
Rampart Bioscience
October 2023

Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases.

Biopharma · La Jolla$85.0M Series A
Harpoon Therapeutics
October 2023

Harpoon Therapeutics is a clinical-stage immunotherapy company focused on the development of novel T-cell recruiting biologic therapies.

Biotechnology · South San Francisco$100.0M Post Ipo Equity
Adela
September 2023

Adela creates develops technologies centered around detecting high-risk conditions like cancer through routine blood tests.

Biotechnology · Foster City$48.0M Series A
Corteria Pharmaceuticals
September 2023

Corteria Pharmaceuticals develops first-in-class drugs in heart failure subpopulations.

Biotechnology · Paris$69.5M Series A

Where OrbiMed invests

Biotechnology20
Health Care13
Therapeutics10
Medical8
Pharmaceutical5
Biopharma5

About OrbiMed's portfolio

How many companies has OrbiMed invested in?

OrbiMed has invested in 289 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does OrbiMed invest in?

OrbiMed's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 14 different industry categories.

What is OrbiMed's largest investment?

Among tracked funding rounds, Cullinan Therapeutics received $280.0M in a Post Ipo Equity round. OrbiMed's total known invested capital is $23.6B.

What is the average investment size for OrbiMed?

OrbiMed's average investment size is $104.0M across its portfolio of 289 companies.

What are OrbiMed's most recent investments?

Recent OrbiMed portfolio additions include MBX Biosciences, Chemomab, Brenig Therapeutics, Magenta Medical, Belenos Biosciences. These companies were founded in 2020 or later.

Reach the founders behind these 289 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →